PEN · Penumbra, Inc.
$318.73
+0.16% last session
End-of-day data · updated 2026-07-28
Market cap
$13B
Enterprise value
$12B
Trailing P/E
73.8
Forward P/E
51.1
Dividend yield
—
Beta
0.70
Avg volume
0M
Employees
5K
2D change
—
5D change
0.50%
10D change
0.37%
30D change
0.90%
60D change
0.37%
MTD change
0.97%
YTD change
2.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-06
Latest call per bank · past 12 months
RBC Capital
Sector Perform$374
+17.3% vs priceCitigroup
Neutral$350
+9.8% vs priceJefferies
Hold$374
+17.3% vs priceWells Fargo
Equal-Weight$374
+17.3% vs priceBank of America
Buy$370
+16.1% vs priceJP Morgan
Overweight$370
+16.1% vs priceMorgan Stanley
Equal-Weight$266
-16.5% vs priceUBS
Buy$335
+5.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $335 → $320 |
| 2026-06-11 | RBC Capital | Reiterates | Sector Perform | $374 |
| 2026-05-07 | Citigroup | Maintains | Neutral | $374 → $350 |
| 2026-05-07 | Evercore ISI Group | Maintains | Outperform | $345 → $335 |
| 2026-02-26 | Evercore ISI Group | Maintains | Outperform | $340 → $360 |
| 2026-01-20 | RBC Capital | Downgrade | Outperform → Sector Perform | $355 → $374 |
| 2026-01-20 | Canaccord Genuity | Downgrade | Buy → Hold | $359 → $374 |
| 2026-01-16 | Jefferies | Downgrade | Buy → Hold | $335 → $374 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.2% above the 50-day MA ($319.47).
- Price vs 200-day MA: Trading 1.8% above the 200-day MA ($314.40).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.38) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($225.54) and high ($359.40).
PEN Price Chart
Loading chart for PEN…
Fundamentals
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
More in Medical Devices
ABT
Abbott Laboratories
$182B -15.0% YTD
SYK
Stryker Corporation
$129B -3.7% YTD
MDT
Medtronic plc.
$108B -10.8% YTD
BSX
Boston Scientific Corporation
$68B -52.3% YTD
EW
Edwards Lifesciences Corporatio
$48B -2.6% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -25.4% YTD
DXCM
DexCom, Inc.
$28B 10.5% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.